At the same time, the quality of evidence derived from two clinical trials on the safety and efficacy of direct factor Xa inhibitors for extended postoperative thromboprophylaxis was deemed low in a very recent update of the American Society of Clinical Oncology guidelines, resulting in a weak recommendation regarding the use of apixaban or rivaroxaban, in addition to a prophylactic dose of low-molecular-weight heparin, after cancer surgery for patients who are candidates for extended prophylaxis [93,99,100]. The gene discussed is F10; the disease is cancer.